Trends and Finance

BioMérieux subsidiary secures DoD contract for infectious disease testing system

BioFire Defense, a subsidiary of BioMérieux, has secured an order-dependent contract with the U.S. Department of Defense (DoD) to provide support for a military-use version of its multiplex polymerase chain reaction infectious disease test system.

September 29, 2023

Harbinger Health raises $140M in series B funding

Biotech company Harbinger Health has raised $140 million in a series B funding round.

September 29, 2023

Day Zero Diagnostics to use $16M in funding to improve management of antibiotic-resistant infections

Day Zero Diagnostics recently raised $16 million to fund the application of whole-genome sequencing and artificial intelligence to antibiotic-resistant infections, facilitating the firm’s goal of changing how infectious diseases are diagnosed.

September 28, 2023

U.S. Attorney’s Office wins $370M judgment in Medicare fraud case

The U.S. Attorney's Office for the Middle District of Florida won a $370 million default judgment against a Kentucky lab owner and his businesses for a lab testing scheme intended to defraud Medicare.

September 28, 2023

Ginkgo Bioworks, Pfizer collaborate on RNA-based therapeutics

Cell engineering company Ginkgo Bioworks has entered into an agreement with Pfizer to discover and develop RNA-based drug candidates.

September 28, 2023

Thermo Fisher Scientific prepared to expand its work at manufacturing facility

Thermo Fisher Scientific executives voiced hopes for expanding work to help combat diseases at its giant $180 million viral vector manufacturing site in Plainville, MA.

September 27, 2023

Invitae receives noncompliance notice from NYSE

San Francisco-based medical genetics company Invitae received a notice of noncompliance from the New York Stock Exchange (NYSE) on September 20 for its stock price closing under $1.00 per share for 30 consecutive days.

September 25, 2023

Rome Therapeutics raises $72M in series B financing

Biotech company Rome Therapeutics has raised a further $72 million in financing to develop medicines for autoimmune diseases and continue its exploration of the “dark genome.”

September 20, 2023

Day Zero Diagnostics completes $16M financing round

Day Zero Diagnostics has completed a $16 million financing round, executed as a convertible note.

September 20, 2023

Broken String Biosciences raises $15M in series A financing round

Broken String Biosciences has closed a $15 million series A financing round.

September 19, 2023

Report: Lack of standardization a ‘huge’ issue during pandemic, problems persist

A lack of standardization of infectious disease consumables was “a huge, unanticipated issue during the pandemic” that still needs to be resolved, according to a report in GenomeWeb.

September 15, 2023

Castle Biosciences Pittsburgh lab receives N.Y. state permit

Castle Biosciences has received a clinical laboratory permit from the New York State Department of Health for its Pittsburgh laboratory.

September 13, 2023

Page 1 of 123

Next Page